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1 Introduction 
Positron Emission Tomography (PET) is one of the most 
important elements of the inventory of nuclear medicine, its significance 
in several fields of medicine; especially in oncological diagnostics is 
undeniable. 
Nowadays, the vast majority of PET examinations is performed 
with only one pharmacon, the 
18
F-Fluoro-deoxy-glucose (
18
F-FDG). 
18
F-
FDG enters cells with the same mechanism as glucose during its 
distribution in the body, then it is phosphorylated intracellularly by a 
hexokinase to FDG-6-phosphate. Afterwards, if the glucose-6-
phosphatase enzyme concentration of the corresponding tissue is low 
(brain, myocardium, most malignant cells), 
18
F-FDG is accumulated in 
proportionate to the carbohydrate metabolism of the tissue, it enters no 
further enzymatic interaction, in those tissues, where glucose-6-
phosphatase enzyme content is detectable, the amount of accumulation 
is decreased. 
Based on the mechanism of distribution and metabolism, it can 
be observed that 
18
F-FDG is a metabolic tracer, which shows significant 
accumulation in several tissues under physiological circumstances and 
in several pathologic processes (tumours, inflammation), which in 
certain cases might lead to significant background activity and to low 
specificity, false positive and false negative results to the process 
desired to be detected. 
With the occurrence of the need towards individualised 
medicine, the widespread of PET and the expansion of knowledge of 
18
F-FDG-PET (and its limits), those research projects are catalysed, 
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which aim at the development of targeted PET-radiopharmacons, which 
are more specific than the 
18
F-FDG. This process is further enhanced in 
nuclear medicine by the need for combination of molecular diagnostics 
and targeted radiotherapy – teragnostic treatments reaching the same 
molecular target, but labelled with different isotopes. 
Neuroendocrine tumours might be mentioned as an example, 
which are typically slow-growing tumours with low 
18
F-FDG 
accumulation, however due to their somatostatin-receptor expression, 
their diagnostics (
111
In-DTPA-Octreotide-SPECT, 
68
Ga-
DOTATOC/TATE-PET) and their therapy (
90
Yttrium-
DOTATOC/DOTATATE, and 
177
Lutetium-DOTATOC/ 
DOTATATE/DOTANOC) are both performed with radiolabelled 
somatostatin-analogues, as it can be seen, with different ratiometals. 
Radionuclide gallium-68 – as positron-source radiometal-
isotope, which is also the labelling isotope of 
68
Ga-DOTATOC/TATE 
with the mentioned clinical relevance – possesses increasing interest in 
PET-related research. Ga-68 with its half-life of 67.7 min is excellently 
suitable for in vivo imaging of peptides, proteins with quick distribution, 
thus the synthesis of specific, targeted radiopharmacons. Besides, for the 
development of appropriate 
68
Ga-labelled radiopharmaceuticals, the 
synthesis and characterisation of novel 
68
Ga-chelators and the mapping 
of biological vectors suitable for 
68
Ga-PET became one of the most 
important tasks of the related, applied radiochemistry. 
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2 Aims 
Ga-68 became the most important radiometal-isotope of PET 
imaging technique in recent decades. Its beneficial physical properties 
(89% β+; t1/2 = 67,7 min; Eaverage(β
+
) = 740 keV) and its cheap 
accessibility – compared to costs of cyclotron installation for the 
application of other, classic positron-source isotopes (
18
F, 
11
C) – through 
68
Ge/
68
Ga-generators makes it suitable for the introduction of novel type 
PET-radiopharmaceuticals synthesized at the diagnostic centre – even in 
a kit-based form in the future. However, careful planning, appropriately 
optimized synthesis and well-established preclinical testing of the 
68
Ga-
labelled radiopharmaceuticals are necessary beforehand. We intended to 
contribute to these processes with our research work, thus we aimed at 
the further examination of two important areas: 
 Testing of chelator molecules suitable for 68Ga-labelling, 
optimization of the conditions of labelling reaction for 
performing efficient radiosyntheses. 
 Synthesis of 68Ga-labelled chelator-biological vector conjugates 
for preclinical testing. 
With these objectives in mind, experimental work was 
performed in the frames of three projects: 
Project 1: Examination of chelators used for Ga-68 labelling with 
traditional, manual labelling methodology, comparative radioanalytical 
examination of NOTA, NOPA, NO2AP and NOPO systems. 
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Project 2: Besides the manual labelling methodology applied for the 
investigation of Ga-68 labelling, the development of alternative, 
microfluidic labelling methodology.  
Project 3: Application of Ga-68 labelling for imaging in biological 
systems, for which cyclic NGR peptide as biological vector and NOTA 
chelator as bifunctional chelator were chosen and its suitability for PET-
imaging was studied in comparison with radiopharmacon 
68
Ga-
NODAGA-[c(RGD)2]. The expression of macromolecule 
Aminopeptidase N targeted by NGR peptide and the integrin targeted by 
RGD-peptide is known in the process of angiogenesis taking place in 
the environment of tumours. 
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3 Materials and methods 
3.1 Comparative examination of 68Ga-labelling properties of 
TACN-based chelators with differing substitution of phosphinic 
and carboxylic groups 
Our first series of experiments were performed according to 
manual labelling protocols in order to reveal direct structure-labelling 
efficiency relationship by 1,4,7-triazacyclononane based chelators. This 
class of compounds were chosen as they possess more advantageous 
stability properties than open-chain Ga-chelators, and based on latest 
results from our cooperation partners the N-substitution of 3 methylene-
phosphinic group to the ring enhances the affinity of the molecule 
towards the formation of chelate with 
68
Ga (so called TRAP-type 
chelator - Triazacyclonane Phosphinic Acid). For further studying this 
effect, we started the comparative investigation of NOTA chelator 
known from literature with three methylene-carboxylic substituents, 
“mixed” chelators with differing substitution of side chains containing 
carboxylic and phosphinic groups (NOPA, NO2AP) and NOPO chelator 
possessing three phosphinic groups. 
Our experiments were started with the elution of 
68
Ge/
68
Ga-
generátor (iThemba) with 1M HCl-solution. The 1.25 ml fraction of the 
eluate with the highest activity concentration was buffered with 0.8 ml 
2.7M HEPES-solution to pH 3.0. From this solution, 90 µl fractions 
were pipetted to the previously prepared 10 µl ligand-solutions. The 
reaction mixtures were kept for 5 min on 25 and 95 ºC, then sample was 
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taken and the radiochemical purity was examined by thin-layer 
chromatography; stationary phase: silica-impregnated paper (Varian 
Inc.), mobile phase 1 M NH4OAc:MeOH/1:1. The papers were read and 
analysed by TLC-scanner (MiniGITA Star, Raytest). 
3.2 Microfluidic optimization of complex-formation reactions of 
68
Ga-chelators 
During our further experiments, we started the development of a 
labelling methodology, which makes the characterisation of 
68
Ga-
chelators possible in a quicker and more efficient manner compared to 
the known manual methods. We aimed at the setting up and testing of 
such system suitable for microfluidic measurements, which can perform 
and analyse complex-formation reactions with 
68
Ga in very small 
solution-volumes and without adding carrier; therefore the system 
would be able to optimise labelling conditions of 
68
Ga-chelators. 
The new system was compared to manual labelling of NOTA 
and NOPO chelators known from literature, quick multiparametric 
reaction-optimization became possible, which was also done with 
NOTA and NOPO chelators. 
Microfluidic labelling was done by the co-injection of two 
solutions of identical volumes; from one of the lines a HEPES-buffered 
68
Ge/
68
Ga-generator (iThemba) eluate collected with 1M aq. HCl-
solution, from the other line also HEPES-buffered chelator solution 
were injected. The pH of the latter solution was set based on previous 
titration with HCl and NaOH-solutions so that the signed pH-values of 
 8 
each measurement were ensured after co-injection of identical volumes 
with the HEPES-buffered eluate. 
While optimization experiments, 20-20 µl solutions were 
reacted in the PEEK-tube thermostated to 95ºC and from this mixture 20 
µl was injected to an online Waters HPLC system. The separation was 
done on an Adsorbosphere XL SCX column, mobile phase: A – water; 
B – 0.2 M aq. tartaric acid solution C – 5% (m/m) aq. NaCl-solution. In 
the case of peptides, HPLC separation was performed on a Kinetex 
column with water/acetonitrile gradient elution. 
68
Ga-activity retention was studied in the PEEK-capillary as 
reactor of the continuous flow system with the help of “blind” solutions 
not containing any chelating moiety. 
The potential suitability of the microfluidic system for 
performing complete radiochemical synthesis was tested applying a 
combined measurement protocol, which involved both retention and 
radiochemical purity examinations for the studied compounds. 
Syntheses were performed in 10-10 µL volumes but in this case, the 
reaction mixtures were not injected to the online HPLC system. By 
these reactions the labelled solutions were collected by dropwise 
fractionation from the continuous flow from the system. Radioactivity 
values were measured instantly with Canberra gamma spectrometer 
using the AUC value of the 511 keV energy peak. Afterwards, sample 
of the solution was injected to HPLC system for the determination of 
radiochemical purity. 
Parameters of the syntheses (pH, ligand concentration) were 
chosen based on results of the multiparametric labelling optimization 
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experiments, and identical parameters were applied with the 
corresponding chelator-bearing biological vector conjugates, 
NODAGA-c(RGD)2 and NOPO-RGD labelling experiments also. 
Reactions were performed in all cases at 95 °C, furthermore in the case 
of NOTA and NOPO, experiments were performed with decreasing 
reaction times (5; 2.5 and 1.25 min) by increasing flow rate in the 
system (0,066; 0,132 and 0,264 mL/min respectively) 
3.3 Synthesis and application of 68Ga-NOTA-c(NGR) for imaging 
Aminopeptidase N (CD13) receptors in vivo 
In these series of experiments, synthesis of NGR peptide was 
performed as first step with Fmoc/tBu strategy, after cyclization of the 
partially protected linear peptide. The purification of the product was 
done by RP-HPLC. The synthesised c[KNGRE]-NH2 was conjugated 
with NOTA chelator on its Lys ε-amino group using p-SCN-Bn-NOTA 
in DMSO. The resulting NOTA conjugated NGR-analogue (NOTA-
c(NGR)) was purified using semipreparative HPLC and was identified 
with ESI-MS. 
The 
68
Ga-labelling of the chelator conjugated vector was 
performed using 1M sodium acetate solution buffering in 
68
Ge/
68
Ga-
generator (iThemba) eluate of 1M HCl-solution, the necessary 
formulation of the solution for the purpose of small animal experiments 
was done by adsorbing the labelled peptide on the surface of Empore
®
 
C18 SD 7 mm/3 mL extraction disc, washing the stationary phase with 
water, elution with EtOH, evaporation of the organic phase and solving 
the radiopharmacon again in isotonic salt solution. 
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A similar method was used for the labelling of NODAGA-
[c(RGD)2] known from literature, but with increased temperature and 
instead of sodium acetate labelling was done in HEPES buffered 
mixture. 
In order to characterise the newly synthesized 
68
Ga-NOTA-
c(NGR), distribution of the radiolabelled compound between 1-octanol 
and PBS solution was measured as logP value for the determination of 
partition coefficient, furthermore its stability was tested in PBS solution 
at 95°C and in rat serum at 37°C. 
Chemically induced rat mesenchymal mesoblastic nephroma 
(NeDe) tumor was used during our small animal experiments in a 
tumour models established in two different anatomical locations. In the 
case of subcutaneous animal model 5 x 10
6
 NeDe tumor cell in 150 μL 
was injected subcutaneously into the left thigh, while for the induction 
of the other tumour model subrenal capsule assay (SRCA) method was 
applied. Here, surgical operation is used for placing Gelaspon
® 
disc 
containing tumour cells under the capsule of the left kidney. For the 
implantation, 5 x 10
6
 NeDe tumor cells in 20 µL saline solution is 
placed on a Gelaspon
® 
disc. The retroperitoneum is opened by 
abdominal section after anasthetization of the animals with isoflurane.  
12 ± 2 days after implantation of the NeDe cells the control and 
tumor-bearing rats are injected via the tail vein with 7.4 ± 0.2 MBq of 
68
Ga-NOTA-c(NGR) or 
68
Ga-NODAGA-[c(RGD)]2. 90 min after the 
administration of the tracer, animals are anastehtized with isoflurane and 
whole body PET examinations were performed (10 min static PET 
imaging in all bed positions) using MiniPET-II small animal PET 
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scanner. CBCT was applied for the anatomical localization of the 
tumors. 
On the following day after PET imaging, the control and 
tumour-bearing rats were anasthsized and injected with 7.4 ± 0.2 MBq 
68
Ga-NOTA-c(NGR) or 
68
Ga-NODAGA-[c(RGD)]2-solutions via the 
tail vein. After 90 min incubation time, rats were euthanized with the 
intraperitoneal injection of 60 mg/kg pentobarbital (Nembutal) and 
blood samples were taken from the heart. Three tissue samples were 
taken from each organs (liver, spleen, kidney, intestine, heart, stomach, 
muscle, lung and tumour) and their activity was measured with a 
calibrated gamma counter. 
During our ex vivo and in vivo blocking experiments the control 
and NeDe-tumor-bearing rats were injected with 200 µg unlabelled 
NOTA-c(NGR) in 100 µL saline (as a blockade, approx. 100 fold of the 
68
Ga-labelled peptides) by intravenous injection 5 min before the 
administration of 
68
Ga-NOTA-c(NGR).  
APN/CD13 expression of the NeDe cell line and the tissue 
samples obtained during the animal experiments were assessed by 
Western blot analysis. 
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4 Results 
4.1 Comparative examination of 68Ga-labelling properties of 
TACN-based chelators with differing substitution of phosphinic 
and carboxylic groups 
Comparative examination of a series of analogous chelators 
with 1,4,7-triazacyclononane ring with differing N-substitution was 
accomplished during this project. As a starting measurement, 
experiments were done at pH 3 and at 95 and 25 °C. Structural 
similarity was exhibited also at the labelling properties of the 
compounds, as expected and a curve of similar shape was presented for 
the examined NOTA, NOPA, NO2AP and NOPO, and a higher ligand 
concentration was necessary for performing quantitative labellings at 
room temperature than at elevated temperature. At this later series of 
experiments, NOPO had a better labelling efficiency compared to 
ligands with mixed substituents and NOTA. Interestingly, the presence 
of a single carboxyl-donor did not influence considerably the labelling 
efficiency at pH 3 when comparing with NOPO. Similarly, the 
monophosphinic-ligand NO2AP showed similar reactivity to NOTA at 
95 °C. However at 25 °C, NO2AP had a better labelling performance 
than NOTA, although maximal radiochemical purity did not exceed 
90% at this case, even at relatively high chelator concentrations. In 
summary, the highest step regarding labelling efficiency was found 
between chelators bearing one or two phosphinic and carboxylic groups. 
Comparing at 50% activity incorporation of the measurements by the 
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investigated temperatures, NOPA could be labelled with three times 
better efficiency than NO2AP, while NOPO and NOTA are separated 
by a factor of ten. 
Almost quantitative labelling efficiency was found by all 
investigated compounds at reactions performed at 95 °C with ligand 
concentration 3 µM and at 25 °C with ligand concentration 30 µM (with 
5 minute reaction time), therefore these values were chosen for further 
investigations, when changing pH of the reaction mixture. When 
performing our reactions at 95 °C, it can be observed that with the 
increase of phosphine-containing substituents, higher labelling yields 
could be reached at lower pH due to the high acidity of phosphinic 
acids. In accordance with previous results, NOPO could be labelled 
quantitatively already at pH 0.5 and even to a small extent at pH 0. On 
the other hand, NOTA showed better performance in the neutral and 
slightly acidic region. Above pH 8, none of the compounds could be 
labelled. 
At room temperature, labelling of all chelators was restricted to 
a much narrower pH region. While NOPO still performed slightly better 
at lower pH, NOPO, NOPA and NO2AP reached their optimum 
between pH 3 and 4. However, 68Ga labelling by the latter ligand again 
did not exceed 90%, while the first two ligands were labelled 
quantitatively. Above pH 4, labelling efficiency of NOPO was 
decreasing to a larger extent than that observed for the other chelators. 
By contrast, and similarly to the situation observed at 95 °C, NOTA 
performed better than the other ligands between pH 4 and 7, with an 
optimum at pH 4. Notably, some radioactivity can be clearly 
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incorporated by NOTA even at pH 8. Overall, radiolabelling results are 
in line with the previously obtained data on TRAP ligands. Due to the 
selectivity of phosphinate-containing TACN derivatives for gallium(III), 
a lower ligand excess is required for efficient radiolabelling with an 
increasing number of phosphinate pendant arms. A similar decrease in 
68Ga incorporation due to presence of the acetate pendant arms has 
been very recently observed for a diacetate-phosphinate TACN 
derivative with the P-bound –CH2CH(PO3H2)2 group. More 
phosphinate pendant arms also means a better labelling of 68Ga in more 
acidic solutions due to the higher acidity of phosphinic acids. On the 
other hand, ligands with more acetate pendant arms are more suitable 
for 68Ga labelling at pH > 4–5. This might be caused by competition 
with the hydroxide anion, as Ga-NOTA complex is more stable based 
on available data than Ga-NOPO complex, thus in the case of a more 
stable complex increase of pH has less effect on chelating properties 
.4.2. Microfluidic optimization of complex-formation reactions of 
68Ga-chelators 
Microfluidic labeling offers an alternative route for the synthesis 
of several well-known 
18
F- and 
11
C-labelled radiopharmaceuticals. 
Nevertheless, in the case of PET radiometals, the numbers of studies are 
very limited. Batch-based PDMS-chip reactor synthesis of 
64
Cu-DOTA-
c (RGDfK) was performed by Wheeler et al.  
In contrast to previous studies, our current examination 
describes a microfluidic methodology, in which a PEEK capillary is 
used as a nonconventional reactor for the noncarrier added synthesis of 
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68
Ga-labelled radiopharmaceuticals. The tube is reeled up inside an air 
thermostat for accurate temperature control. NOTA and NOPO are well-
known for their 
68
Ga chelation properties; thus, they were chosen as 
model compounds for testing the operation of the new system. 
Moreover, new HPLC method was developed for the separation of 
labelled chelators and “free” 68Ga. We compared the results of the 
manual labelling and microfluidic procedure. The methods provided 
slightly different results only in extremely low concentrations of NOPO. 
Such a deviation was considered typical for the threshold limits.  
Further evaluation of the continuous flow microfluidic system 
was focused on the utilization of the high-throughput and minimal 
human interaction properties of this setup. Here, we performed 
sequential analysis of labelling properties of the chelators NOTA and 
NOPO under microfluidic conditions over a broad range of reaction 
parameters: 0.01–100 μM ligand concentration and 1–9 pH range. The 
temperature and the reaction time were maintained stably at 95 °C for 5 
min.  
Similarly to previous reports, NOPO with its phosphinic 
pendant arms exhibited an extended labelling profile in comparison with 
NOTA. This was observed at the lowest ligand concentration needed for 
achieving quantitative labelling. Additionally, radiochemical purity over 
95% was obtained on a broader pH scale. NOPO preserves its affinity 
towards 
68
Ga in highly acidic pH values of 1 and 2 as well.  
A PEEK capillary apparatus was chosen as a non-conventional 
reactor, since this device has been successfully utilized as a component 
of multiple-use radiochemical systems due to its compatibility with 
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basic, acidic, and organic solvent and high temperature (up to 134 °C) 
conditions. Additionally, being an organic polymer, no significant 
reactivity was expected with the reagents used for 
68
Ga-labelling 
reactions. In our system, 
68
Ga retention was measured at carefully 
defined pH values, since aqueous Ga(III) can be present in many forms. 
In these studies, an interesting retention pattern was observed: 
significant 
68
Ga retention was measured between pH values of 3–7 with 
the maximum at pH 3. Depending on the composition of the solution, 
aqueous gallium is known to form different hydroxo-complexes 
[Ga(OH)n] in this pH region, but it is also known to be more dominant 
with the increase of the pH value of the solution. Other hypothesized 
reason for the trend towards retention may be a consequence of the 
buffer system. HEPES is supposed to form a weak complex with 
aqueous Ga(III). 
68
Ga, as a component of an organic complex, might 
possess a higher affinity for adsorption than aqueous Ga(III) alone. 
Alteration in the charge at pH 3 can affect the existence of the proposed 
weak complex and, therefore, the activity retention itself. Besides – and 
slightly supporting our hypothesis – significant role of pH 3.0 can be 
observed in current labellings, as the highest labelling efficiency with 
the lowest necessary ligand concentration was found at pH 3.0 by both 
examined materials, which might originate from an easier reaction from 
a weaker HEPES-Ga-complex compared to different gallium-
hydroxocomplexes. 
Test syntheses were also performed to determine the suitability 
of PEEK reactor for preparative purpose also. In these experiments, 
activity retention was measured in the presence of different 
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chelators/chelator–peptide conjugates. Parameters of the system optimal 
for synthesis of desired conjugates were chosen with the objective of 
achieving required robustness since, in a continuous flow system, 
dilution with the carrier fluid can be expected. In these experiments, 
concentrations of 10 μM for NOTA and 1 μM for NOPO were selected, 
both at pH 3.0. These concentration values are at least one measurement 
step higher than the lowest ligand concentration needed for quantitative 
labelling. Moreover, when productivity of the system was tested at 
higher pH values, RCP over 95 % was still obtained. In these test runs, 
identical reaction parameters were also used for the analogous peptide 
conjugates of the chelators as well.  
NOTA, NOPO, and their respective analogues conjugated with 
RGD peptide; NODAGA-c(RGD)2 and NOPO-RGD were studied, and 
the analysis of final reaction mixtures demonstrated that only marginal 
or negligible retention (<5%) may be expected in the presence of the 
chelating moieties investigated in the present study. 
4.3. Synthesis and application of 
68
Ga-NOTA-c(NGR) for imaging 
Aminopeptidase N (CD13) receptors in vivo 
This study aimed to investigate newly synthesized 
68
Ga-NOTA-
c(NGR) as an innovative molecular probe for the evaluation of APN 
expression in experimental tumors. The synthesis of the cyclic NGR 
peptide (c[KNGRE]-NH2) was developed in literature with the 
preparation of the cyclic peptide using on resin cyclization. In these 
experiments, we introduced an efficient alternative route for the 
synthesis of c[KNGRE]-NH2 cyclic peptide. In this case, the linear 
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protected peptide (Boc- Lys(ClZ)-Asn(Trt)-Gly-Arg(Pbf)-Glu(OtBu)-R) 
was built up on solid support by standard Fmoc/tBu strategy followed 
by removal of a semi-protected peptide (H-Lys(ClZ)-Asn-Gly-Arg-Glu-
NH2) from the resin using TFA cleavage mixture. The amide bond 
formation between the N-terminal amino group and the c-carboxyl 
group of glutamic acid was carried out in diluted DMF solution by the 
aid of coupling agents. Prior to the removal of ClZ protecting group 
with liquid HF, the semi-protected cyclic peptide was purified by RP-
HPLC. The cyclic NGR peptide was prepared successfully by the 
application of this procedure and no deamidation through succinimide 
ring closure was observed in any stage of the synthesis. As a following 
step, pure c[KNGRE]-NH2 peptide was successfully conjugated with p-
SCN-Bn-NOTA, then the resulting NOTA-c( NGR) was easily labelled 
afterwards with 
68
Ga with a RCP of 95%< and a specific activity of 
5.13–5.92 GBq/µmol. 
The in vitro experiments demonstrated that newly synthesized 
68
Ga-NOTA-c(NGR) is highly hydrophilic (logP = - 2.77 ± 0.12) and 
was also found to be stable both in PBS at increased temperature (T = 
95 °C) for 1 h and in rat serum at 37 °C for 2 h; these results 
demonstrate that 
68
Ga-NOTA-c(NGR) is an appropriate candidate for 
further experiments. 
Ex vivo and in vivo biodistribution studies on control animals 
revealed that 
68
Ga-NOTA-c(NGR) was mainly excreted from the 
kidney, due to its hydrophilic properties that has been proved by the 
partition coefficient. On the other hand, the uptake of the tracer in other 
organs was very low, especially in the abdomen in contrast to the 
68
Ga-
 19 
NODAGA-[c(RGD)]2, where the abdominal organs (liver, spleen, 
intestines) showed radiotracer uptake after 90 min incubation time. This 
moderate accumulation of 
68
Ga-NODAGA-[c(RGD)]2 in the abdominal 
organs correlated well with other studies, where the biodistribution of 
68
Ga-DOTA-NGR and 
68
Ga-NOTA-NGR molecules were investigated. 
Furthermore, the low activity of other organs also allowed for high 
quality images with low background and high tumor-to-muscle ratios to 
be obtained. 
In our study, we investigated the tumor specific accumulation of 
68
Ga-NOTA-c(NGR) as a new molecular probe for imaging 
angiogenesis-marker expression, comparing with the commercially 
available αvβ3 integrin receptor specific 
68
Ga-NODAGA-[c(RGD)]2 on 
two different animal models using a small animal PET scanner. In this 
paper, we test different types of administrations of nephroblastoma 
(NeDe) tumor cells to rats to investigate the expression of APN/CD13 in 
primary tumors. Among the administrations, local tumor formation was 
induced by subcutaneous injection, and subrenal (SRCA) implantation 
of NeDe tumor cell line. Comparing the two different tumor models 
(SRCA versus subcutaneous), we found that the accumulation of both 
investigated radiotracers in primary tumors was higher in the SRCA 
model. This difference stems from the site of the tumor cell 
implantation. The most commonly used method for the induction of 
primary tumors is the subcutaneous injection of cancer cells. This kind 
of transplantation is ectopic and lacking orthotopic tissue 
microenvironments. Vascularization and tumor growing are more 
intensive when tumor cells are implanted at orthotopic site (e.g. renal 
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tumors into the kidney or subcapsular space), and the favorable 
microenvironment of this site may promote higher expression of 
angiogenic markers; furthermore subserve tumor cell proliferation and 
generation of metastases. 
By taking the SUVmean values, the uptake of 
68
Ga-
NOTAc(NGR) of the primary tumors (subcutaneously growing NeDe 
tumor and tumor on the left kidney was relatively higher than that of the 
68
Ga-NODAGA-[c(RGD)]2 uptake, and this difference was significant 
(p ≤ 0.01) in the case of SUVmax and T/M ratios at 90 min p.i.. Our 
results suggest that 
68
Ga-NOTA-c(NGR) bears the potential to 
outperform even dimeric RGD-targeted tracers, which might originate 
from the different structure and stability of the cyclic NGR peptide as a 
homing device. 
After blocking by unlabelled NOTA-c(NGR), the tumor uptake 
of 
68
Ga-NOTA-c(NGR) reduced significantly (p ≤ 0.01) in both primary 
tumors. Similarly to previously mentioned studies with other 
68
Ga-
labeled NGR-conjugates with human xenograft tumors, our successful 
blocking results suggest that 
68
Ga-labelled NOTA-c(NGR) also 
specifically binds to the APN/CD13 receptors, which presence on NeDe 
tumors and metastases was proved by western blot experiments. 
Angiogenesis is prerequisite in the multistep process of 
generating metastasis when cancer cells spread from primary sites to 
distant places. APN/CD13 may play a role in the invasion of cancer 
cells by enhancing their invasive capacity and metastatic behavior and 
by degrading the extracellular matrix to promote malignant cell 
invasion. Here, we used a syngenic metastasis animal model to 
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investigate the expression of APN/CD13 by 
68
Ga-NOTA-c(NGR) not 
only in primary tumors, but also in metastatic lymph nodes. The 
implantation of NeDe tumor cells under the left kidney capsule caused 
tumor metastasis in the thoracal parathymic lymph nodes (PTNs) and in 
the mesenteric lymph nodes. By ex vivo experiments we found 
APN/CD13 receptor specific accumulation of 
68
Ga-NOTA-c(NGR) in 
metastatic lymph nodes. These results suggest that 
68
Ga-NOTA-c(NGR) 
is a promising molecular probe for the detection of metastases. 
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5 Summary 
Radioisotope gallium-68 is a positron-source, which is available 
from generator, which makes quick, efficient and in the future even kit-
based synthesis of PET-radiopharmaceuticals possible, as due to its 
metallic properties a wide scale of biological vectors can be labelled 
with it using a chelator moiety. Our experiments focused on the 
synthesis, characterization and preclinical application of 
68
Ga-labelled 
complexes as they are gaining increasing relevance in nuclear medicine. 
Chemical properties of the chelator moiety have a determinative 
role during the synthesis of 
68
Ga-PET-radiopharmaceuticals. During one 
of our series of experiments we performed the comparative 
radioanalytical examination of TACN-based chelators. Our results 
reveal that at least two phosphinic substituents  are essential for the 
excellent 
68
Ga-complex-formation efficiency described by TRAP-type 
chelators, therefore one of the phosphinic group of the TRAP pattern 
can be changed to other donor. The presence of carboxyclic group can 
help complex-formation at neutral and mildly acidic pHs. The income of  
this structure-complex-formation property relationships can be useful 
for planning of the chelators of the future. 
For the previously described characterisation, primarily manual 
labellings are used in the literature, which however is time-consuming, 
can be hard to reproduce and can be produced with relatively high 
amount of substance. Contrarily, we successfully tested a microfluidic 
system during our research project, which is suitable for performing and 
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analysing 
68
Ga-labelling reactions automatically. We were able to 
provide complete characterization of radiolabelling efficiency of 
macrocyclic chelators in an automated manner, furthermore we 
demonstrated that it is possible to performe 
68
Ga-labellings in a 
continuous flow microfluidic system with an excellent radiochemical 
purity (95%<) without significant activity retention (<5%). 
In our further studies, we synthesized a new, 
68
Ga-labelled 
radiopharmaceutical, the 
68
Ga-NOTA-c(NGR) with high radiochemical 
purity. The radioligand showed high chemical stability, and we tested it 
with APN/CD13+ NeDe cell line and syngeneic small animal tumour 
model for the detection of tumours and metastases successfully. 
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